Medulloblastoma with extensive nodularity

Summary

Medulloblastoma with extensive nodularity (MONDO:0016710) is a disease and 1 clinical trial. Top therapeutic interventions include cyclophosphamide anhydrous. A subtype of medulloblastoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	medulloblastoma with extensive nodularity
Mondo ID	MONDO:0016710
Orphanet	251858
DOID	DOID:3873
NCIT	C5407
UMLS	C1334970
MedGen	233759
GARD	0017214
Is cancer (heuristic)	no

Also known as: cerebellar neuroblastoma · MBEN · medulloblastoma with extensive nodularity · medulloblastoma with extensive nodularity and advanced neuronal differentiation · nodular medulloblastoma

Disease family

This is a subtype of medulloblastoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › brain disorder › cerebellar disorder › cerebellar neoplasm › medulloblastoma › medulloblastoma with extensive nodularity

Related subtypes (13): brain stem medulloblastoma, large cell medulloblastoma, cerebellar vermis medulloblastoma, adult medulloblastoma, melanotic medulloblastoma, childhood medulloblastoma, medullomyoblastoma with myogenic differentiation, anaplastic/large cell medulloblastoma, desmoplastic/nodular medulloblastoma, classic medulloblastoma, medulloblastoma WNT activated, medulloblastoma SHH activated, medulloblastoma non-WNT/non-SHH

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02017964	PHASE2	COMPLETED	Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic Medulloblastoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CYCLOPHOSPHAMIDE ANHYDROUS	4	1